ADMA BIOLOGICS, INC.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Repurchases of Equity Securities
In May 2025, the Board authorized the share Repurchase Program of up to $500.0 million of the Company’s outstanding shares of common stock. The Repurchase Program does not obligate the Company to acquire any particular amount of its common stock, and may be modified, suspended, or terminated at any time. The Repurchase Program has no expiration date.
During the three months ended March 31, 2026, the Company repurchased approximately 331,548 shares of common stock under the Repurchase Program at a total cost of $5.2 million.
Accelerated Share Repurchase Program
On March 2, 2026, the Company entered into an ASR Agreement with JPMorgan to repurchase $125.0 million of shares of the Company’s common stock under the Repurchase Program. During the period ended March 31, 2026, the Company initially received 6,422,608 shares related to the ASR Agreement. The remaining shares under the ASR Agreement are expected to be repurchased by August 2026.
The table below reflects shares of common stock we repurchased during the first quarter of 2026:
| For the Month Ended · Total Number of Shares Purchased · Average Price Paid per Share(1) · Total Number of Shares Purchasedas Part of Publicly AnnouncedPlans or Programs · Approximate Dollar Value of shares they may yet be Purchased Under the Plans or Programs(2) | |||||
|---|---|---|---|---|---|
| January 31, 2026 | - | $ | - | - | $468,059,744 |
| February 28, 2026 | 234,368 | $15.75 | 234,368 | $464,368,655 | |
| March 31, 2026 | 6,519,788 | $16.37 | 6,519,788 | $357,666,638 | |
| Total | 6,754,156 | $16.06 | 6,754,156 | ||
(1) Includes broker commissions.
(2) Shares were repurchased pursuant to our share repurchase program publicly announced on May 5, 2025. There is no expiration date for this share repurchase program. The authorization to repurchase shares will end when we have repurchased the maximum number of shares authorized, or if we have determined to terminate such program.
Item 3.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.